FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
FibroBiologics, a clinical-stage biotechnology company, announced a Board-approved 1-for-20 reverse stock split effective March 30, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement. The reverse split reduces the number of outstanding shares significantly while maintaining the existing authorized share count and does n…